Tirofiban
| Code | Size | Price |
|---|
| CDX-T0153-M005 | 5 mg | £108.00 |
Quantity:
| CDX-T0153-M025 | 25 mg | £401.00 |
Quantity:
| CDX-T0153-M100 | 100 mg | £1,183.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
MK-383; L-700,462; (2S)-2-(Butylsulfonylamino)-3-{4-[4-(4-piperidyl)butoxy}phenyl propanoic acid; N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine
Appearance:
Off-white powder.
CAS:
144494-65-5
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.Protect from light and moisture.
Hazards:
H315, H319, H335
InChi:
InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
InChiKey:
COKMIXFXJJXBQG-NRFANRHFSA-N
Long Description:
Chemical. CAS: 144494-65-5. Formula: C22H36N2O5S. MW: 440.6. Synthetic Synthetic non-peptide selective glycoprotein (GP) IIb/IIIa receptor antagonist/inhibitor. Anticoagulant, specifically, an anti-platelet aggregation inhibitor.
MDL:
MFCD05237246
Molecular Formula:
C22H36N2O5S
Molecular Weight:
440.6
Package Type:
Vial
Precautions:
P261, P305, P351, P338
Product Description:
Synthetic non-peptide selective glycoprotein (GP) IIb/IIIa receptor antagonist/inhibitor. Anticoagulant, specifically, an anti-platelet aggregation inhibitor.
Purity:
>99% (HPLC)
Signal word:
Warning
SMILES:
CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O
Solubility Chemicals:
Sligthly soluble in ethanol or water.
Source / Host:
Synthetic
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
(1) G.D. Hartman, et al.; J. Med. Chem. 35, 4640 (1992) | (2) K. Peerlinck, et al.; Cirulation 88, 1512 (1993) | (3) M.S. Egbertson, et al.; J. Med. Chem. 37, 2537 (1994) | (4) J.S. Barret, et al.; Clin. Pharmacol. Ther. 56, 377 (1994) | (5) J.J. Lynch, et al.; J. Pharmacol. Exp. Ther. 272, 20 (1995) | (6) B.S. Coller, et al.; J. Clin. Invest. 100, S57 (1997)